Medicure Inc. (TSX:MPH)(AMEX:MCU), a cardiovascular drug discovery and development company is pleased to report positive results with its FDA Fast Tracked cardioprotective product, MC-1, in the Phase II MEND-CABG study. The MEND-CABG study is a double blind, parallel group, randomized, placebo-controlled study in 901 patients who underwent coronary artery bypass graft (CABG) surgery. Based on the positive results, the Company plans to move forward with a pivotal Phase III clinical development program for MC-1.
